Endpoints News 17. Feb. 2026 FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher
Endpoints News 14. Feb. 2026 Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more
Endpoints News 13. Feb. 2026 Lilly appeals retatrutide classification ruling in case that could impact compounders
Endpoints News 13. Feb. 2026 Lundbeck migraine prevention drug succeeds in Phase 2, advancing new therapy class
Endpoints News 13. Feb. 2026 Immunic's private placement; Vertex's cystic fibrosis data in young kids
Endpoints News 13. Feb. 2026 Paul Hudson couldn’t quite get Sanofi over the hump; PROTAC developer Arvinas appoints CEO